Sarcopenic ObesityPROSO-COPDNCT06735573
Protein, Sarcopenic Obesity, and COPD
An observational study of Sarcopenic Obesity and Chronic Obstructive Pulmonary Diseases, run by University of Aberdeen at 1 site in United Kingdom.
Trial summary
Both sarcopenic obesity and chronic obstructive pulmonary diseases (COPD) are common conditions that mainly affect middle-aged and older adults. Previous research has shown that increased dietary intake of total and plant-based protein is associated with a lower risk of sarcopenic obesity, using data from the EPIC… Read more about this study
- Who is it for?
- Ages 55 years and older, women only
- Conditions the study is for
- Sarcopenic Obesity, Chronic Obstructive Pulmonary Diseases
- What is being tested?
- the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomes
- How many people
- 13 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Jan 2026to 27 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Women with clinically diagnosed COPD, from GP practices in Aberdeen,United Kingdom, through the Primary Care Research Network.
Who may be able to join
- Women.
- Clinically diagnosed with COPD.
- Aged 55 years or older.
Who cannot join
- Male.
- Women who are 54 years or younger.
- Those who have dementia.
- Unable to read or write in English.
- Unable to attend the Human Intervention Studies Unit.
- Those within one year life expectancy.
- Those who have cancer.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Observational Study to Explore the Relationship Between Dietary Protein Intake and the Prevalence of Sarcopenic Obesity in Adult Female With Chronic Obstructive Pulmonary Disease (COPD): A Pilot Study
Both sarcopenic obesity and chronic obstructive pulmonary diseases (COPD) are common conditions that mainly affect middle-aged and older adults. Previous research has shown that increased dietary intake of total and plant-based protein is associated with a lower risk of sarcopenic obesity, using data from the EPIC Norfolk study. Furthermore, a systematic review and meta-analysis showed that having sarcopenic obesity was associated with significantly impaired lung function outcomes. Other research has shown that increased intake of dietary protein leads to a better treatment outcome for respiratory diseases. The aim of this pilot observational study is to investigate, in more detail, the relationship between the quantity and source of dietary protein intake, the prevalence of sarcopenic obesity, and lung function, in a small cohort of older female participants with COPD. The study will also consider the role of inflammation in relation to sarcopenic obesity and lung function outcomes. This study will help to improve the understanding of the relationship between sarcopenic obesity and lung function outcomes, and how dietary protein intake and inflammation can affect this relationship and each of the outcomes.
- Being tested
- the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomes
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomesOther
Also called the level of inflammation (plasma CRP)
Primary Objective The primary objective is to measure the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomes, in older female participants with clinically diagnosed COPD.
Secondary Objectives The secondary objective is to investigate whether the level of inflammation (plasma CRP) is associated with the intake of total, plant-based and animal-based protein, with the prevalence of sarcopenic obesity, and with lung function outcomes.
What is being measured
The primary outcome is the main question the study is designed to answer.
Association between dietary protein and the prevalence of sarcopenic obesity
Association between dietary intake of total, plant-based and animal-based protein and the prevalence of sarcopenic obesity.
Measured: through study completion, an average of 1 year
Secondary outcomes (1)
Association between dietary protein and lung functions outcomes
Association between dietary intake of total, plant-based and animal-based protein and lung functions outcomes (Forced Vital Capacity (FVC), Forced Expiratory Volume in The First Second(FEV1), and The Ratio of Forced Expiratory Volume in The First Second to Forced Vital Capacity (FEV1/FVC ratio)).
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2024
- Study start1 Jan 2026
- Primary completion27 Aug 2026
- Study completion27 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sarcopenic ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Aberdeen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06735573
- Sponsor's protocol ID
- T Baabbad
- Other IDs
- University of Aberdeen
- Acronym
- PROSO-COPD
- Status last verified
- Sep 2026
- First submitted
- 5 Dec 2024
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: It is not yet known if there will be a plan to make IPD available.
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study to Explore the Relationship Between Dietary Protein Intake and the Prevalence of Sarcopenic Obesity in Adult Female With Chronic Obstructive Pulmonary Disease (COPD): A Pilot Study
- ClinicalTrials.gov ID
- NCT06735573
- Acronym / sponsor ID
- PROSO-COPD / T Baabbad
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- University of AberdeenUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 27 Aug 2026 (actual)
- Study completion
- 27 Aug 2026 (actual)
- First posted
- 16 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Both sarcopenic obesity and chronic obstructive pulmonary diseases (COPD) are common conditions that mainly affect middle-aged and older adults. Previous research has shown that increased dietary intake of total and plant-based protein is associated with a lower risk of sarcopenic obesity, using data from the EPIC Norfolk study. Furthermore, a systematic review and meta-analysis showed that having sarcopenic obesity was associated with significantly impaired lung function outcomes. Other research has shown that increased intake of dietary protein leads to a better treatment outcome for respiratory diseases. The aim of this pilot observational study is to investigate, in more detail, the relationship between the quantity and source of dietary protein intake, the prevalence of sarcopenic obesity, and lung function, in a small cohort of older female participants with COPD. The study will also consider the role of inflammation in relation to sarcopenic obesity and lung function outcomes. This study will help to improve the understanding of the relationship between sarcopenic obesity and lung function outcomes, and how dietary protein intake and inflammation can affect this relationship and each of the outcomes.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 55 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Women with clinically diagnosed COPD, from GP practices in Aberdeen,United Kingdom, through the Primary Care Research Network.
Key inclusion criteria (3 listed)
- Women.
- Clinically diagnosed with COPD.
- Aged 55 years or older.
Key exclusion criteria (7 listed)
- Male.
- Women who are 54 years or younger.
- Those who have dementia.
- Unable to read or write in English.
- Unable to attend the Human Intervention Studies Unit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomesAlso: the level of inflammation (plasma CRP)Primary Objective The primary objective is to measure the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomes, in older female participants with clinically diagnosed COPD. Secondary Objectives The secondary objective is to investigate whether the level of inflammation (plasma CRP) is associated with the intake of total, plant-based and animal-based protein, with the prevalence of sarcopenic obesity, and with lung function outcomes. | Other | – |
Primary outcome
Association between dietary protein and the prevalence of sarcopenic obesity
Time frame: through study completion, an average of 1 year
Association between dietary intake of total, plant-based and animal-based protein and the prevalence of sarcopenic obesity.
1 secondary outcome
Association between dietary protein and lung functions outcomes
Time frame: through study completion, an average of 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
- Individual participant dataSharing planned: Undecided. It is not yet known if there will be a plan to make IPD available.
Related trials for Sarcopenic Obesity
Not yet recruiting
Effects of the EatWelLog App on Enhancing Diet Management for Older Adults With Sarcopenic Obesity
Sacropenic Obesity
RecruitingObservational study
GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes
Obesity, Sarcopenia
Enrolling by invitation
Whole-body Vibration Training on the Elderly With Combined Bilateral Knee Osteoarthritis
Knee OA, Sarcopenic Obesity
Active, not recruiting
The Effect of Acupuncture on Sarcopenia and Obesity in Patients With Sarcopenic Obesity.
Sarcopenic Obesity, Acupuncture Treatment
RecruitingPhase 4
GLP-1R Actions on Muscle and the Skeleton
Musculoskeletal Abnormalities, Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcopenic Obesity and Chronic Obstructive Pulmonary Diseases, run by University of Aberdeen at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Association between dietary protein and the prevalence of sarcopenic obesity (time frame: through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.